Neuromuscular Disorders are a broad group of conditions that impair muscle function either directly (muscles) or indirectly (nerves or neuromuscular junctions). These disorders cause muscle wasting and can also cause twitching, spasticity or paralysis.
Featured Learning Zones
Examples of neuromuscular disorders are:
- Amyotrophic lateral sclerosis - motor neurone diseases
- Multiple sclerosis
- Myasthenia gravis
- Spinal muscular atrophy
Related news and insights
Biogen Inc. has announced that the first patient has been treated in the global clinical study, RESPOND. The Phase IV study will examine the clinical benefit and assess the safety of Spinraza (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy Zolgensma (onasemnogene abeparvovec).
Osmotica Pharmaceuticals plc announced that the FDA has issued a Complete Response Letter (“CRL”) regarding the Company's New Drug Application (“NDA”) seeking approval for the investigational agent arbaclofen extended release ("ER") tablets to treat spasticity resulting from multiple sclerosis.
Genentech, a member of the Roche Group announced that the FDA has approved a shorter two-hour infusion time for Ocrevus (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). The approval was based on data from the randomized, double-blind ENSEMBLE PLUS study.
This 2015 revised guideline replaces former versions. It includes all newly approved or licensed treatments for MS and represents a consensus concerning their use.